On 16 March 2024, New Delhi Police arrested Neeraj Chauhan and others for selling fake anti-cancer drugs to patients at a ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

Pharma Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation By Angus Liu Jun 13, 2025 10:50am Merck & Co. Keytruda head and neck cancer PD-1/L1 ...

Nonetheless, though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. Merck is also working on different strategies to drive Keytruda's long-term ...

Merck is also working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers. Studies found patients taking Keytruda can reduce ...

Pharma FDA limits Merck's Keytruda, Bristol Myers' Opdivo in stomach cancer By Angus Liu Jun 9, 2025 10:50am Merck & Co. Keytruda Bristol Myers Squibb Opdivo ...

VIENNA, Va., June 18, 2025--FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine.

Alvotech and Dr Reddy’s Laboratories announced today they have entered a collaboration agreement to co-develop, manufacture and commercialise a biosimilar candidate to Keytruda (pembrolizumab ...